NKT Therapeutics Inc.
This article was originally published in Start Up
In therapies that target the immune system, T cells have become an important target because of the role they play in cell-mediated immunity, directing macrophages, natural killer cells, and cytotoxic T lymphocytes towards invaders. But a subset of T cells, called natural killer T cells, may afford more precise control because they straddle both the adaptive immune system and the more generalized innate immune system that reacts more rapidly and non-specifically. NKT Therapeutics hopes to take that refinement one step further by focusing on a subset of NKT cells that don't vary from individual to individual. Moreover, the invariant T-cell receptor that they carry is identical in everyone.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Set Sights on Flu," features profiles of Alios BioPharma, Immune Targeting Systems, Marinomed Biotechnologie and Vivaldi Biosciences. Plus these Start-Ups Across Health Care: CardiAQ Valve Technologies, NKT THerapeutics, SPOC Inc.,and Sutro Biopharma.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.